Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus EYDENZELT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus EYDENZELT.
DUEXIS vs EYDENZELT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
EYDENZELT (bexarotene) is a retinoid that selectively binds to and activates retinoid X receptors (RXRs), which regulate gene expression involved in cell differentiation, proliferation, and apoptosis. It induces apoptosis and inhibits cell growth in malignant T-cells.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
1 mg subcutaneously once weekly.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is approximately 12-14 hours, allowing once-daily dosing with steady-state reached within 3-5 days.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Primarily renal excretion as unchanged drug (approximately 70-80%) and minor fecal elimination (≤10%). Biliary excretion is negligible.
Category C
Category C
NSAID/H2 Antagonist Combination
NSAID